Effects of supplementation with two probiotic strains on metabolic profile, hormonal status, oxidative stress, and quality of life in women with polycystic ovary syndrome: A study protocol for a randomized clinical trial

Published date: Jan 27 2026

Journal Title: International Journal of Reproductive BioMedicine

Issue title: International Journal of Reproductive BioMedicine (IJRM): Volume 23, Issue No. 11

Pages: 927 – 936

DOI: 10.18502/ijrm.v23i11.20547

Mahsa ShiraniNutrition and Food Security Research Center, Isfahan University of Medical Sciences, Isfahan

Mohammad BagherniyaNutrition and Food Security Research Center, Isfahan University of Medical Sciences, Isfahan

Omid SadeghiResearch Center for Food Hygiene and Safety, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd

Hatav Ghasemi TehraniIsfahan Medical Obstetrics and Gynecology Group, Reproductive Sciences and Sexual Health Research Center, Isfahan University of Medical Sciences, Isfahan

Mohammad Hadi EskandariDepartment of Food Science and Technology, School of Agriculture, Shiraz University, Shiraz

Manoj SharmaDepartment of Social and Behavioral Health, School of Public Health, University of Nevada, Las Vegas, Nevada

Gholamreza Askariaskari@mui.ac.irNutrition and Food Security Research Center, Isfahan University of Medical Sciences, Isfahan

Background: Polycystic ovarian syndrome (PCOS) is a common endocrine disorder in women, associated with insulin resistance, ovulatory dysfunction, hyperandrogenism, and inflammation. Current treatments often focus on symptoms rather than underlying causes, emphasizing the need for comprehensive strategies. Recently, probiotics have emerged as a safe and cost-effective nutritional option for managing metabolic issues.

Objective: This study aims to evaluate the effects of Lactobacillus helveticus and Bifidobacterium longum supplementation on the cardiometabolic profile, hormonal status, oxidative stress, and quality of life in women with PCOS.

Materials and Methods: We will conduct a double-blind, placebo-controlled, randomized trial involving 90 women with PCOS from Shahid Beheshti hospital, Isfahan, Iran. Recruitment will begin on June 20, 2024, and is expected to be completed by June 20, 2025. Participants will be randomly assigned to receive either a daily probiotic capsule containing Lactobacillus helveticus and Bifidobacterium longum or a placebo. The study will assess the impact of these probiotic strains on cardiometabolic profile, hormonal status, oxidative stress, mental health, quality of life, sleep quality, and clinical symptoms in women with PCOS. All parameters will be evaluated before and after the intervention.

Discussion: Elevated insulin levels and gut microbiota imbalances significantly contribute to the development of PCOS. Growing evidence suggests that gut dysbiosis is linked to sex hormone levels and estrous cycles. We hypothesize that probiotic supplementation in individuals with PCOS will improve hormonal, metabolic, inflammatory, and antioxidant markers compared to those receiving a placebo.

Keywords: Probiotics, Polycystic ovary syndrome, Testosterone, Sex hormone-binding globulin, Randomized clinical trial

[1] Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: A brief systematic review. J Hum Reprod Sci 2020; 13: 261–271.

[2] Wang R, Mol BWJ. The Rotterdam criteria for polycystic ovary syndrome: Evidence-based criteria? Hum Reprod 2017; 32: 261–264.

[3] Teede HJ, Tay CT, Laven JJ, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol 2023; 189: G43-G64.

[4] He Y, Wang Q, Li X, Wang G, Zhao J, Zhang H, et al. Lactic acid bacteria alleviate polycystic ovarian syndrome by regulating sex hormone related gut microbiota. Food Funct 2020; 11: 5192–5204.

[5] Jiang S, Liu A, Ma W, Liu X, Luo P, Zhan M, et al. Lactobacillus gasseri CKCC1913 mediated modulation of the gut-liver axis alleviated insulin resistance and liver damage induced by type 2 diabetes. Food Funct 2023; 14: 8504–8520.

[6] Tabrizi R, Ostadmohammadi V, Akbari M, Lankarani KB, Vakili S, Peymani P, et al. The effects of probiotic supplementation on clinical symptom, weight loss, glycemic control, lipid and hormonal profiles, biomarkers of inflammation, and oxidative stress in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Probiotics Antimicrob Proteins 2022; 14: 1–14.

[7] Młynarska E, Wasiak J, Gajewska A, Steć G, Jasińska J, Rysz J, et al. Exploring the significance of gut microbiota in diabetes pathogenesis and management: A narrative review. Nutrients 2024; 16: 1938.

[8] Zhang X, Zhang Y, Luo L, Le Y, Li Y, Yuan F, et al. The beneficial effects of a multispecies probiotic supplement on glycaemic control and metabolic profile in adults with type 1 diabetes: A randomised, double-blinded, placebo-controlled pilot-study. Diabetes Metab Syndr Obes 2023; 16: 829–840.

[9] Romijn AR, Rucklidge JJ, Kuijer RG, Frampton C. A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression. Aust N Z J Psychiatry 2017; 51: 810–821.

[10] Rode J, Edebol Carlman HMT, König J, Repsilber D, Hutchinson AN, Thunberg P, et al. Probiotic mixture containing lactobacillus helveticus, bifidobacterium longum and lactiplantibacillus plantarum affects brain responses toward an emotional task in healthy subjects: A randomised clinical trial. Front Nutr 2022; 9: 827182.

[11] Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med 2013; 158: 200–207.

[12] Ji X, Chen J, Xu P, Shen S, Bi Y. Effect of probiotics combined with metformin on improvement of menstrual and metabolic patterns in women with polycystic ovary syndrome: A randomized clinical trial. Gynecol Endocrinol 2022; 38: 856–860.

[13] Richardson C. Household manuals. In: Smith E, Kesson A. The elizabethan top ten: Definining print popularity in early modern England. 1st Ed. London: Routledge; 2013.

[14] Welk GJ, Kim Y, Stanfill B, Osthus DA, Calabro AM, Nusser SM, et al. Validity of 24-h physical activity recall: Physical activity measurement survey. Med Sci Sports Exerc 2014; 46: 2014–2024.

[15] Nasiri-Amiri F, Ramezani Tehrani F, Simbar M, Montazeri A, Mohammadpour RA. Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): Development and psychometric properties. Qual Life Res 2016; 25: 1791–1801.

[16] Tehrani FR, Minooee S, Azizi F. Validation of a simplified method to assess hirsutism in the Iranian population. Eur J Obstet Gynecol Reprod Biol 2014; 174: 91–95.

[17] Bernardis E, Shou H, Barbieri JS, McMahon PJ, Perman MJ, Rola LA, et al. Development and initial validation of a multidimensional acne global grading system integrating primary lesions and secondary changes. JAMA Dermatol 2020; 156: 296–302.

[18] Elham B, Somayeh S, Afsaneh S-B, Azadeh G, Mohammadreza G, Saba S, et al. The effect of metformin in the treatment of intractable and late onset acne: A comparison with oral isotretinoin. Iran J Dermatol 2019; 22: 47–52.

[19] Fabbrocini G, Cantelli M, Masarà A, Annunziata M, Marasca C, Cacciapuoti S. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol 2018; 4: 203–211.

[20] Khoshdel A, Shekari A, Paydary K, Shekari I. Alopecia areata: The role of stressful events and an estimate of lifetime risk in first-degree relatives. J Arch Mil Med 2016; 4: e36377.

[21] Lee D. The convergent, discriminant, and nomological validity of the depression anxiety stress scales-21 (DASS-21). J Affect Disord 2019; 259: 136–142.

[22] Chehri A, Nourozi M, Eskandari S, Khazaie H, Hemati N, Jalali A. Validation of the Persian version of the Pittsburgh sleep quality index in elderly population. Sleep Sci 2020; 13: 119–124.

[23] Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes Metab Syndr Obes 2020; 13: 3611–3616.

[24] Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380: 711–719.

[25] Chaudhuri A. Polycystic ovary syndrome: Causes, symptoms, pathophysiology, and remedies. Obes Med 2023; 39: 100480.

[26] Zeb F, Osaili T, Obaid RS, Naja F, Radwan H, Cheikh Ismail L, et al. Gut microbiota and time-restricted feeding/eating: A targeted biomarker and approach in precision nutrition. Nutrients 2023; 15: 259.

[27] Sun Y, Gao S, Ye C, Zhao W. Gut microbiota dysbiosis in polycystic ovary syndrome: Mechanisms of progression and clinical applications. Front Cell Infect Microbiol 2023; 13: 1142041.

[28] Guo Y, Qi Y, Yang X, Zhao L, Wen S, Liu Y, et al. Association between polycystic ovary syndrome and gut microbiota. PloS One 2016; 11: e0153196.

[29] Sankararaman S, Noriega K, Velayuthan S, Sferra T, Martindale R. Gut microbiome and its impact on obesity and obesity-related disorders. Curr Gastroenterol Rep 2023; 25: 31–44.

[30] Hasan AU, Rahman A, Kobori H. Interactions between host PPARs and gut microbiota in health and disease. Int J Mol Sci 2019; 20: 387.